Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person degarelix [extracellular region]
| Class:Id | ProteinDrug:9718373 |
|---|---|
| _displayName | degarelix [extracellular region] |
| _timestamp | 2021-03-24 14:22:01 |
| compartment | [Compartment:984] extracellular region |
| created | [InstanceEdit:9718363] Jassal, Bijay, 2021-03-17 |
| disease | [Disease:1655499] prostate cancer |
| literatureReference | [LiteratureReference:9718404] Evaluation of degarelix in the management of prostate cancer [LiteratureReference:9724511] In search of the molecular mechanisms mediating the inhibitory effect of the GnRH antagonist degarelix on human prostate cell growth |
| modified | [InstanceEdit:9724537] Jassal, Bijay, 2021-03-24 |
| name | degarelix FE200486 Firmagon® |
| referenceEntity | [ReferenceTherapeutic:9718399] degarelix [Guide to Pharmacology:5585] |
| stableIdentifier | [StableIdentifier:9718427] R-ALL-9718373.1 |
| (hasMember) | [DefinedSet:9718382] GNRHR peptide antagonists [extracellular region] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by degarelix [extracellular region] (9718373)
